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Abstract 
Introduction: Autologous fat transfer (AFT) is widely adopted for breast reconstruction, but its long-
term oncologic safety is still not clearly established. The aim of the present study was to compare the 
10-year loco-regional recurrence (LRR)-free and distant metastases (DM)-free survival probabilities 
in AFT vs. control patients, also evaluating the impact of AFT in different intrinsic molecular 
subtypes of breast cancer. 
Materials and Methods: 464 AFT patients were exactly matched with a cohort of 3,100 control 
patients treated between 2007 and 2017. A multivariate survival analysis was performed accounting 
for all variables related to LRR and DM, including adjuvant/neoadjuvant treatments. End-points were 
analyzed both overall and in each molecular subtype. 
Results: LRR occurred in 6.4% of AFT and in 5.0% of control patients (p=0.42), while DM were 
observed respectively in 7.7% and 5.4% of cases (p=0.20). AFT showed no effect on the 10-year 
LRR-free survival probability (adjusted HR 0.87, 95%CI 0.43-1.76, p=0.69) or the 10-year DM-free 
survival probability (adjusted HR 0.82, 95%CI 0.43-1.57, p=0.55). Luminal A patients treated by 
AFT showed a decreased LRR-free survival probability (HR 2.38, 95%CI 0.91-6.17, Log-Rank 
p=0.07), which was significantly lower than controls after 80 months (Log-Rank p=0.02). No 
differences in the 10-year event-free survival probability were found in Luminal B, HER2-positive 
or triple-negative patients. 
Conclusion: AFT does not increase breast cancer recurrence, with the possible exception of late LRRs 
for Luminal A patients, but further clinical and preclinical data are required to better clarify this data. 
The use of AFT should not be discouraged. 
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1 Introduction 
Autologous fat transfer (AFT) consists in adipose fat tissue liposuction from donor sites, its 
purification and its relocation to breast sites, to refill a volume defect or to correct other asymmetries 
or irregularities after breast-conserving surgery or mastectomy [1, 2]. This technique is widely 
adopted by breast surgeons, and its use has risen over time [3]. However, concerns about an increased 
risk of cancer recurrence have been raised, and the oncological safety of AFT has been questioned 
[4-7]. Indeed, adipose-derived mesenchymal stem cells are transferred together with adipose tissue 
during AFT, stimulating angiogenesis and stroma remodeling, thus being responsible for the cosmetic 
success of lipofilling [8, 9]. On the other hand, preclinical studies showed that adipocytes and 
adipokines, being part of the tumor microenvironment, may play a role in cancer occurrence and 
progression, possibly being related to recurrence [10-13]. A few case-control studies based on large 
populations are available today, which suggest that local recurrence rates do not seem increase after 
AFT [7, 14]. At the same time, rigorous evidence analyzing long-term oncologic outcomes and which 
also considers adjuvant treatments and biomolecular subtypes (BMS) of breast cancer are still scarce 
[14]. The aim of the present study was to assess the long-term oncologic impact of AFT, by comparing 
the 10-year loco-regional and distant recurrence-free survival probability in patients treated for breast 
cancer with or without AFT, also evaluating the correlation with BMS and adjuvant therapies in a 
long-term follow up. 
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2 Material and methods 
2.1 Study population 
Patients were retrospectively collected from the prospectively-maintained database of the EUSOMA-
accredited Breast Unit of ICS Maugeri Hospital from January 2007 to December 2017. The 464 
patients who received at least one AFT were selected and exactly matched with a cohort of control 
patients extracted from the remaining 3,100 women who were not subjected to AFT. Inclusion criteria 
were: proven diagnosis of breast cancer and any surgery including lumpectomy, nipple-sparing 
mastectomy or skin-sparing mastectomy with reconstruction. Patients with benign diseases, distant 
metastases at diagnosis, a previous diagnosis of breast cancer or other cancer, or with relevant data 
missing were excluded from the study. 
 
2.2 Study design and endpoints 
Due to the non-random design of the study, an exact match of categorical variables and a range of 
values for continuous variables were designated, matching patients treated with AFT and control 
patients according to the subsequent variables: age, histopathology, staging, BMS and grading. BMS 
were approximated as follows, based on the histopathological features of breast cancer: luminal A 
(positive hormone receptors and negative HER2, Ki67 <14%), luminal B (positive hormone receptors 
and any HER2 status, Ki67 ≥14%), HER2-enriched (negative hormone receptors and positive HER2), 
and triple-negative (negative hormone receptors and negative HER2). AFT patients and controls were 
matched allowing a 1:4 ratio at most. To provide a reliable comparison between AFT and control 
patients in terms of follow-up, each selected control had an event-free follow-up for at least as long 
as the period between breast cancer surgery and the AFT of the matched case. The main endpoints 
were 1) the 10-year loco-regional recurrence (LRR)-free survival probability and 2) the 10-year 
distant metastases (DM)-free survival probability in patients treated with AFT vs. controls. LRR was 
defined as the occurrence of ipsilateral breast cancer or nodal disease at axillary, internal mammary 
and/or supraclavicular level, proven on core biopsy. DM was defined as the occurrence of distant 
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lesions with computed tomography and positron emission tomography features suggestive of 
malignancy, even if not biopsy-proved. A multivariate survival analysis was performed accounting 
for all variables related to LRR and DM, including adjuvant or neoadjuvant treatments and BMS. 
Secondary endpoints were: 1) cancer-related death rate, 2) impact of AFT on LRR and DM stratified 
by number of AFT procedures, time between breast cancer surgery and AFT, and type of surgery, 
and 3) evaluation of long-term oncologic safety of AFT according to each BMS.  
 
2.3 AFT technique 
Indications for AFT were: contour defects, asymmetry, scar retraction and fibrosis, or volume defect 
after any type of breast cancer surgery; thinning of peri-prosthetic tissues after mastectomy and breast 
reconstruction, particularly in the case of increased risk of implant exposure; capsular contracture 
after implant reconstruction. Preferred donor sites were abdominal subcutaneous tissue or fatty tissue 
from thighs. The chosen area was infiltrated with Klein’s solution (average 200 mL) prepared as 
follows: 60 mg of lidocaine, 7.5 mg of ropivacaine and 1 mg of adrenaline mixed in 1 L of cold saline 
solution at 0.9%. Infiltration was performed through the subdermal tissue of the donor site using an 
18G needle connected to a 50 mL syringe. After infiltration, a 5 mm skin incision was performed on 
the donor site and a blunt-tipped Coleman cannula with a diameter of 4 mm was inserted. Liposuction 
by negative pressure was then started. The aspirated adipose tissue was then centrifuged (IEC 
Medispin-6 Krackeler Scientific Inc., Albany, NY) at 2700xg for 3-4 minutes to separate adipocytes 
from erythrocytes, lysed cells and serum. The purified fat tissue was then collected and slowly 
injected into the subdermal space of the receiving breast site. 
 
2.4 Statistical analysis 
Differences between AFT and control patients after exact matching were assessed to verify the 
heterogeneity of the study population. Variables were reported as mean ± standard deviations or as 
absolute numbers and percentages. Categorical variables were compared using a χ2 test or Fisher 
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exact test when the sample size was less than or equal to 5, while continuous variables were compared 
using a Student’s T test or non-parametric Wilcoxon test in case of the variable’s non-normal 
distribution. AFT and control patients were compared by a Cox proportional hazards regression 
model, including variables significantly associated with the outcomes, such as the type of 
adjuvant/neoadjuvant therapy (hormone therapy, chemotherapy and radiation therapy) and BMS to 
avoid any bias. The 10-year LRR-free and DM-free survival probabilities were estimated by the 
Kaplan-Meier method, both globally and in each BMS. Statistical significance was set at p<0.05 (two-
tailed). Data analysis was performed using SAS software (v. 9.4, SAS Institute Inc., Cary, USA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Results 
3.1 Distribution of baseline variables and type of adjuvant treatments after exact matching 
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After exact matching, 830 patients were included for outcomes analyses: 233 AFT (28.1%) and 597 
control patients (71.9%). The distribution of baseline variables and BMS were balanced between 
groups, as reported in Table 1. AFT patients were treated more frequently by mastectomy when 
compared to controls (76.8% vs. 25.6%, p<0.0001). Consequently, control patients were more likely 
to receive radiation therapy when compared to AFT cases (74.9% vs. 45.9%, p<0.0001). In particular, 
whole breast radiotherapy with or without boost was offered to 45.8% of AFT patients and to 53.6% 
of the control group, thoracic wall and/or loco-regional radiotherapy were performed respectively in 
38.3% and 25.4% of cases, and other types of radiotherapy were delivered in 15.9% and 21.0% of 
patients (p=0.053), Table 1. Chemotherapy was administered in 54.1% of AFT patients vs. 44.6% of 
control patients (p=0.04); neoadjuvant treatment was proposed respectively in 12.0% and 8.4% of 
cases (Table 1). Chemotherapy regimen was based on anthracyclines with or without taxanes in 
64.7% of AFT vs. 57.1% of control patients, and trastuzumab was administered respectively in 26.1% 
and 34.8% of cases; in the remaining cases, cyclophosphamide with methotrexate and fluorouracil 
(5.9% vs. 5.0%) or other regimens (3.4% vs. 3.1%) were offered (p=0.48). 
 
3.2 Long-term outcomes and event-free survival probabilities between AFT vs. no AFT patients 
Mean follow-up after breast cancer surgery was 74.1 (±40.4) months in AFT patients vs. 63.8 (±37.1) 
months in controls (p=0.0015). In the AFT group, the mean time interval from breast cancer surgery 
to the first lipofilling procedure was 22.9 (±19.7) months, matched with an event-free interval which 
was at least equal in control patients. The, mean follow-up period after the first lipofilling procedure 
was 51.2 (±35.0) months. LRR occurred in 6.4% of AFT patients and in 5.0% of control patients 
(p=0.42), while DM were observed respectively in 7.7% and 5.4% of cases (p=0.20). Furthermore, 
no difference was observed in cancer-related death rates, being 5.1% in AFT vs. 3.4% in controls 
(p=0.23). All these data are reported in Table 2. AFT and control patients showed comparable 10-
year LRR-free survival probability curves, with a hazard ratio (HR) for AFT vs. no AFT equal to 0.96 
(95%CI 0.52-1.80, Log-Rank test p=0.91), see Figure 1a. Also, 10-year DM-free survival 
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probabilities were similar between AFT and control patients (HR 1.24, 95%CI 0.69-2.21, Log-Rank 
test p=0.47), as shown in Figure 1b. 
 
3.3 Multivariate survival analysis of AFT vs. no AFT on LRR-free and DM-free survival probabilities 
After adjusting for potential confounding variables by means of the Cox regression model, AFT 
confirmed no effect on 10-year LRR-free survival probability, with a HR equal to 0.87 (95%CI 0.43-
1.76, p=0.69). No variable resulted to be independently associated with LRR. AFT was not associated 
with decreased 10-year DM-free survival probability (HR 0.82, 95%CI 0.43-1.57, p=0.55). The only 
factor independently associated with DM was the need for adjuvant (HR 2.81, 95%CI 1.10-7.14, 
p=0.03) or neoadjuvant (HR 5.63, 95%CI 2.01-15.75, p=0.001) chemotherapy. Menopausal status 
and body mass index showed no significant association with LRR or DM. The Cox multivariate 
analysis is reported in Table 3. 
 
3.4 Impact of number of AFT procedures, time between oncologic surgery and AFT and type of 
surgery on outcomes 
Taking all AFT patients (n=464) into consideration, no correlation was found between the number of 
lipofilling procedures and the occurrence of LRR or DM (respectively Log-rank p=0.28 and p=0.45), 
as reported in Table 4. Performing AFT early (<1 year from oncologic surgery) was not associated 
with increased events (for LRR Log-rank p=0.44, for DM Log-rank p=0.74), despite a higher 
proportion of early AFT observed among recurrent patients (36.0% vs. 24.2%). Use of AFT after 
breast-conserving surgery, nipple-sparing mastectomy or skin-sparing mastectomy was not related to 
LRR (Log-rank p=0.85) or DM (Log-rank p=0.33). 
 
 
3.5 Impact of AFT on outcomes in different BMS of breast cancer 
A sub-analysis was performed comparing the effect of AFT vs. no AFT on 10-year LRR-free and 
DM-free survival probabilities in different BMS of breast cancer (Figure 2). AFT was not associated 
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with increased frequency of LRR (HR 2.38, 95%CI 0.91-6.17, Log-Rank p=0.07) and DM (HR 2.18, 
95%CI 0.94-5.06, Log-Rank p=0.06) in Luminal A patients, considering the overall follow-up. 
However, starting from 80 months, survival probability curves were different between the remaining 
AFT patients (n=45) and controls (n=100) for LRR (Log-Rank p=0.02, Figure 2a) but not for DM 
(Log-Rank p=0.06, Figure 2b). No differences were observed for Luminal B (LRR: HR 0.51, 95%CI 
0.16-1.60, Log-Rank p=0.24, Figure 2c; DM: HR 1.05, 95%CI 0.39-2.81, Log-Rank p=0.91, Figure 
2d) and HER2-positive breast cancers (LRR: HR 1.97, 95%CI 0.33-11.89, Log-Rank p=0.45, Figure 
2e; DM: HR 0.79, 95%CI 0.08-7.76, Log-Rank p=0.84, Figure 2f). Also, no differences were found 
in triple-negative breast cancers, where no events were encountered among AFT patients (LRR: Log-
Rank p=0.07, Figure 2g; DM: Log-Rank p=0.12, Figure 2h). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Discussion 
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At least 41 non-overlapping studies have previously reported LRR and DM rates after AFT, but the 
oncologic safety of lipofilling still remains debated, despite the fact that the great majority of evidence 
suggests similar outcomes between AFT and control patients [7]. We observed that LRR and DM 
rates were similar between AFT and control patients after exact matching according to baseline 
cancer-related features. After adjusting for confounders in a regression model accounting for adjuvant 
treatments and BMS, AFT was still not associated with increased LRR (HR 0.87, p=0.69) or DM 
(HR 0.82, p=0.55). Recently, a large meta-analysis on 4,292 patients demonstrated a non-significant 
incidence rate difference in LRR of -0.15% per year between AFT and control patients, providing 
robust evidence of AFT safety after breast cancer [7]. However, the mean follow-up from AFT 
procedure was only 2.7 years for included studies. Considering the long-lasting natural history of 
breast cancer, such a short follow-up is a common concern due to the risk of under-estimation in 
cumulative incidence of events [15, 16]. In the present study, a longer follow-up is available for AFT 
patients, with a mean of 51.2 months after the first lipofilling procedure. As can be expected, a longer 
overall follow-up was available for AFT patients (74.1 vs. 63.8 months, p=0.0015), since AFT is 
generally reserved for patients after a certain disease-free interval. To better control for this bias, we 
matched control patients with a disease-free period at least equal to the period from breast cancer 
surgery to the first lipofilling in AFT patients. This solution was first proposed by Petit and colleagues 
in their landmark study on 321 AFT patients, providing a reliable comparison which showed no 
impact of AFT on LRR (HR 1.11, p=0.792) [17]. Also, Krastev et al. reported a longer overall follow-
up for AFT patients compared to control, being respectively 9.3 vs. 8.6 years but again, the LRR-free 
interval of control patients was matched with the period between breast cancer surgery and exposure 
to AFT [15]. No effect of AFT on LRR was found, with a HR of 0.63 (p=0.33), confirming that 
evidence of higher risk after AFT is lacking. 
 
A major point of concern is the unbalanced proportion of patients who underwent mastectomy vs. 
breast-conserving surgery in the two groups, with mastectomy performed in 76.8% of AFT patients 
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vs. only 25.6% of controls (p<0.0001) after exact matching. Since AFT can correct soft tissue 
deformities, skin flap thinning, capsular contracture and post-mastectomy pain syndrome [18, 19], it 
is not surprising that AFT was adopted after mastectomy in the great majority of patients in this study 
and in previous literature [7, 16, 20-22]. Due to the different distribution of types of surgery in the 
two groups, AFT patients received significantly less radiotherapy when compared to controls (45.9% 
vs. 74.9%, p<0.0001). Apparently, such differences could represent a bias for our findings. However, 
it is currently well-established that lumpectomy with radiotherapy carries a similar LRR risk when 
compared to mastectomy [23, 24], and that biological features of breast cancer together with adjuvant 
treatments predict LRR better than the extent of surgery [25]. Therefore, the difference in the type of 
surgery is conceptually irrelevant in terms of the LRR rate, considering that the clinical, pathological 
and biological characteristics of patients were exactly matched and taken into account in the 
multivariate analysis. Furthermore, the type of surgery was in any case included in the multivariate 
survival analysis together with the use of AFT, and it confirmed that there was no association with 
LRR (HR 0.84, p=0.71) or DM (HR 1.09, p=0.84).  
 
In our institution, loco-regional irradiation is proposed only in patients with >3 positive nodes 
irrespective of the type of surgery, thus avoiding post-mastectomy radiotherapy in N1 patients. Since 
the stage was similar between groups, no significant differences were found in the type of irradiation, 
being loco-regional radiotherapy offered in 38.3% of AFT patients vs. 25.4% of controls (p=0.053). 
Moreover, the use of radiotherapy was considered in multivariate analysis, but it was not related to 
LRR (HR 1.04, p=0.93) or DM (HR 0.71, p=0.40). Consequently, it is unlikely that loco-regional 
irradiation in AFT patients could have  biased survival analyses. 
 
Indeed, some studies suggest that in AFT after breast-conserving surgery, adipose tissue may cross-
talk with surrounding dormant residual cancer cells, thus promoting LRR [26, 27]. In this study, the 
type of surgery was equally distributed among AFT patients with and without LRR (p=0.72), and 
 12 
breast-conserving surgery was performed respectively in 26.4% and 20.0% of cases. This further 
excludes the role of the type of surgery in LRR and confirms the safety of AFT after breast-conserving 
surgery. The largest population of patients undergoing breast-conserving surgery followed by AFT 
comes from a recent study by Petit, which confirmed that AFT is a safe procedure even after 
lumpectomy [28]. Petit and Silva-Vergara suggested that AFT performed within 3 years after breast 
cancer surgery is related to increased risk of LRR [22, 26]. In the present study, the great majority of 
patients (about 70%) received the first AFT procedure within 3 years from oncologic surgery, but this 
has not resulted in an increased event rate (p=0.44 for LRR and p=0.74 for DM). 
 
No study is known to have specifically addressed the risk of AFT on LRR or DM in relation to 
fundamental predictors of outcome such as BMS [7, 15-17, 22, 26]. Luminal cancers are related to 
late recurrences and HER2-positive or triple-negative cancers to early events [29-32]. Considering 
the global follow-up of Luminal A, no significant decrease in LRR-free (HR 2.38, p=0.07) or DM-
free (HR 2.18, p=0.06) survival probabilities was observed in AFT patients. However, after 80 
months a significant trend toward a lower LRR-free survival probability seems to be observed in AFT 
patients affected by Luminal A cancers (p=0.02). Despite this intriguing finding, it should be noted 
that after 80 months only 145 Luminal A patients were still on follow-up, representing less than one-
third of the initial Luminal A population. Therefore, no definitive conclusions on the impact of AFT 
on the Luminal A subtype may be drawn. There is no previous study which reports this effect of AFT 
on late LRR in Luminal A cancers, and this could be related to the shorter mean follow-up available 
in other studies, which could lead to missing late LRR typically associated with Luminal cancers [7]. 
Kronowitz et al. demonstrated that AFT patients undergoing hormone therapy had a three-fold risk 
of LRR when compared to controls [16]. The authors suggested that hormone-related pathways could 
somehow crosstalk with adipose-derived mesenchymal stem cells promoting recurrence, but no clear 
explanation could be offered. Also Petit described that LRRs significantly increased after AFT in 
DCIS [26]. Notably, 80% of tumors were estrogen receptor-positive. Therefore, in both Kronowitz 
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and Petit studies, it is not clear whether the different outcome of AFT reported in those patient subsets 
might be better related to a Luminal-type BMS. Another finding of the present study is the 
unexpectedly low rate of LRR among lipofilled triple-negative patients (p=0.07). This data could be 
explained by the fact that triple-negative breast cancer typically recurs with early events, thus 
excluding the indication for AFT [31]. Therefore, triple-negative AFT patients were mostly 
represented by cases with a longer disease-free survival compared to controls. 
 
Study limitations 
This study presents some limitations. First, it is not a randomized clinical trial therefore, patients were 
retrospectively allocated into two groups (AFT vs. no AFT) potentially associated with different LRR 
and DM risks. Indeed, AFT is often performed on young patients undergoing mastectomy for locally-
advanced tumors at presentation, with higher T stages and more frequent axillary involvement [33]. 
This main difference accounts for the unbalanced distribution of variables observed in Table 1, 
particularly the overwhelming use of mastectomy in the AFT group, despite the matching of 
preoperative variables. However, exact matching and subsequent multivariate analysis were 
performed to properly address these biases. Second, radiotherapy was used differently between 
groups and loco-regional irradiation was favored slightly in AFT patients. Therefore, radiotherapy’s 
possible role in biasing LRR analysis may remain unclear. Third, the exact matching of AFT and 
control patients greatly reduced the study population, thus flawing the study’s statistical power. In 
particular, data on the impact of AFT on Luminal A patients after 80 months might not be robust 
enough to support relevant conclusions. 
5 Conclusions 
AFT could be safely proposed in the setting of multi-modal adjuvant treatment. A possible increase 
in late LRRs for Luminal A patients undergoing AFT cannot be excluded however, further clinical 
and preclinical data are required to better elucidate this point.  
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Tables 
Table 1. Distribution of baseline variables after exact matching 
 
AFT 
(n = 233) 
No AFT 
(n = 597) 
p-value 
Age at diagnosis (years) 49.4 (±9.0) 50.7 (±8.9) 0.07 
Body mass index (mean, Kg/m2) 23.8 (±4.8) 24.5 (±4.9) 0.09 
Menopausal status    
 19 
Pre-menopausal 134 (57.5%) 342 (57.3%) 0.95 
Post-menopausal 99 (42.5%) 255 (42.7%)  
Type of surgery 
Lumpectomy 54 (23.2%) 444 (74.4%) 
<0.0001 
Mastectomy 179 (76.8%) 153 (25.6%) 
Histological Type 
DCIS 26 (11.2%) 62 (10.4%) 
0.84 Ductal invasive carcinoma 173 (74.2%) 455 (76.2%) 
Lobular invasive carcinoma 34 (14.6%) 80 (13.4%) 
Grading 
G1 23 (9.9%) 72 (12.1%) 
0.23 G2 126 (54.1%) 345 (57.8%) 
G3 84 (36.0%) 180 (30.1%) 
Staging 
Stage 0 31 (13.3%) 72 (12.1%) 
0.05 
Stage I 94 (40.3%) 289 (48.4%) 
Stage II 71 (30.5%) 178 (29.8%) 
Stage III 37 (15.9%) 58 (9.7%) 
Biomolecular subtype 
Luminal A 120 (51.5%) 336 (58.3%) 
0.48 
Luminal B 75 (32.2%) 181 (30.3%) 
HER2+ 16 (6.9%) 28 (4.7%) 
TNBC 22 (9.4%) 52 (8.7%) 
Hormone therapy 
Yes 186 (79.8%) 475 (79.6%) 
0.93 
No 47 (20.2%) 122 (20.4%) 
Chemotherapy 
No 107 (45.9%) 331 (55.4%) 
0.04 Yes, neoadjuvant 28 (12.0%) 50 (8.4%) 
Yes, adjuvant 98 (42.1%) 216 (36.2%) 
Radiation therapy 
Yes 107 (45.9%) 447 (74.9%) 
<0.0001 
No 126 (54.1%) 150 (25.1%) 
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Table 2. Long-term outcomes between lipofilled vs. non-lipofilled patients 
 
AFT 
(n = 233) 
No AFT 
(n = 597) 
p-value 
Loco-regional recurrence 
Yes 15 (6.4%) 30 (5.0%) 
0.42 
No 218 (93.6%) 567 (95.0%) 
 21 
Distant metastases 
Yes 18 (7.7%) 32 (5.4%) 
0.20 
No 215 (92.3%) 565 (94.6%) 
Cancer-related death 
Yes 12 (5.1%) 20 (3.4%) 
0.23 
No 221 (94.9%) 577 (96.6%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Multivariate survival analysis of AFT vs. no AFT on 10-year LRR-free and DM-free 
survival probabilities 
 Loco-regional recurrence Distant Metastases 
 
Hazard 
Ratio 
95% CI p-value 
Hazard 
Ratio 
95%CI p-value 
Age at diagnosis 1.03 (0.98-1.08) 0.29 1.02 (0.98-1.07) 0.35 
Body mass index 0.95 (0.88-1.03) 0.19 0.93 (0.86-1.00) 0.05 
 22 
Menopausal status       
Pre-menopausal vs. post-
menopausal 
1.58 (0.66-3.79) 0.31 1.35 (0.58-3.12) 0.49 
Type of surgery       
Lumpectomy vs. mastectomy 0.84 (0.34-2.10) 0.71 1.09 (0.47-2.51) 0.84 
AFT       
Performed vs. not performed 0.87 (0.43-1.76) 0.69 0.82 (0.43-1.57) 0.55 
pT stage       
Early vs. locally-advanced breast 
cancer 
1.47 (0.65-3.33) 0.36 0.61 (0.33-1.13) 0.12 
pN stage       
pN0 vs. pN2-3 1.14 (0.35-3.76) 0.83 0.42 (0.16-1.07) 0.07 
pN1 vs. pN2-3 1.45 (0.45-4.67) 0.54 0.54 (0.23-1.30) 0.17 
Biomolecular subtype       
Luminal A vs. TNBC 0.63 (0.16-2.54) 0.51 0.47 (0.10-2.25) 0.34 
Luminal B vs. TNBC 1.00 (0.27-3.78) 1.000 0.41 (0.09-1.92) 0.26 
HER2+ vs. TNBC 1.54 (0.46-5.22) 0.49 1.27 (0.34-4.71) 0.72 
Chemotherapy       
Yes: adjuvant vs no 0.91 (0.39-2.11) 0.83 2.81 (1.10-7.14) 0.03 
Yes: neoadjuvant vs. no 2.62 (0.97-7.09) 0.06 5.63 (2.01-15.75) 0.001 
Hormone therapy       
Performed vs. not performed 0.70 (0.24-2.04) 0.51 2.41 (0.58-9.97) 0.22 
Radiation therapy       
Performed vs. not performed 1.04 (0.45-2.42) 0.93 0.71 (0.31-1.60) 0.40 
 
 
 
Table 4. Impact of number of AFT procedures, time between oncologic surgery and AFT and type 
of surgery on LRR and DM 
All AFT patients 
(n = 464)  
Loco-regional recurrence Distant metastases 
 
No 
(n = 439) 
Yes 
(n = 25) 
Log-rank 
p-value 
No 
(n = 425) 
Yes 
(n = 39) 
Log-rank 
p-value 
Number of AFT 
procedures   
    
 23 
1 165 (37.6%) 5 (20.0%) 0.28 159 (37.4%) 11 (28.2%) 0.45 
2 213 (48.5%) 16 (64.0%)  206 (48.5%) 23 (59.0%)  
≥3 61 (13.9%) 4 (16.0%)  60 (14.1%) 5 (12.8%)  
Time from cancer 
surgery to first AFT   
    
<1 year 106 (24.2%) 9 (36.0%) 0.44 107 (25.2%) 8 (20.5%) 0.74 
1-3 years 198 (45.1%) 11 (44.0%)  190 (44.7%) 19 (48.7%)  
>3 years 135 (30.7%) 5 (20.0%)  128 (30.1%) 12 (30.8%)  
Type of surgery       
Lumpectomy 116 (26.4%) 5 (20.0%) 0.85 115 (27.1%) 6 (15.4%) 0.33 
Skin-sparing mastectomy 254 (57.9%) 15 (60.0%)  243 (57.2%) 26 (66.7%)  
Nipple-sparing mastectomy 69 (15.7%) 5 (20.0%)  67 (15.8%) 7 (17.9%)  
 
 
 
  
 
 
 
 
 
 
 
 
Figure captions 
Figure 1 Survival probability curves of AFT vs. control patients. a) 10-year loco-regional recurrence-
free survival probability; b) 10-year distant metastases-free survival probability. AFT, autologous fat 
transfer. 
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Figure 2 10-year survival probability curves of AFT vs. control patients for each biomolecular 
subtype of breast cancer. a) loco-regional recurrence and b) distant metastases in Luminal A; c) loco-
regional recurrence and d) distant metastases in Luminal B; e) loco-regional recurrence and f) distant 
metastases in HER2-positive; g) loco-regional recurrence and h) distant metastases in triple-negative 
breast cancer. 
